Medication info
Empagliflozin/Metformin Extended-Release Tablets 5/1000 mg (Empagliflozin, Metformin)

Empagliflozin/Metformin Extended-Release Tablets 5/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Pale yellow rectangular extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202502002 · Approved 2025.07.31 · Insurance code 647805920

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine is determined based on each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of the 10/1000 mg or 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Special populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine should be discontinued immediately. Elderly patients For patients aged 75 years and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Blood sugar control issues in adults with type 2 diabetes
  • inadequately controlled blood sugar
  • cardiovascular disease
View approved original text

This medication helps improve blood sugar control in adult patients with type 2 diabetes when used with diet and exercise. It is particularly suitable for adult patients whose blood sugar is not sufficiently controlled and may also be used in those with cardiovascular disease. However, detailed effects on cardiovascular events should be referred to in professional information. This medication is effectively used for diabetes management.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine is determined based on each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of the 10/1000 mg or 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Special populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine should be discontinued immediately. Elderly patients For patients aged 75 years and older, consider renal function and the risk of volume depletion.

Precautions

This medication is a combination drug used for the treatment of type 2 diabetes, helping to regulate blood sugar levels. It should not be administered to patients with impaired kidney function and should be avoided in those with acute kidney problems or severe infection. This medication is not used in patients with severe liver dysfunction or acute or unstable heart failure. During treatment, a rare complication known as lactic acidosis can occur, so if symptoms (such as fatigue, muscle pain, difficulty breathing, abdominal pain, etc.) arise, consult a physician immediately. Also, this medication may increase the risk of hypoglycemia when used with other diabetes medications, so patients taking insulin or sulfonylurea group drugs may require dosage adjustments. Urinary infections or genital infections may occur, so prompt treatment should be sought if such symptoms appear. This medication can cause fluid loss, so precautions should be taken to prevent dehydration or fluid deficit. Pregnant women, women who may become pregnant, and nursing mothers are advised not to take this medication. Elderly patients may have reduced kidney function, so regular kidney function tests are necessary, and it is safe to avoid the maximum dosage. This medication should be swallowed whole without breaking, crushing, or chewing the tablets, although the tablet shell may pass in the stool, which is normal. Patients facing surgery should stop taking this medication 48 hours prior to surgery and resume after kidney function is normally restored post-surgery. When undergoing tests that use iodine contrast agents, this medication should be stopped before and after the tests, and it should be re-administered after confirming normal kidney function. Excessive alcohol consumption may increase the risk of lactic acidosis, so alcohol should be avoided during treatment. This medication can lower vitamin B12 levels, so checks for vitamin B12 deficiency may be needed during prolonged use. Finally, regularly check blood sugar control status while taking this medication and consult healthcare personnel immediately if unusual symptoms occur.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decrease and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • nausea
  • vomiting
  • diarrhea
Show 195 more
  • abdominal pain
  • anorexia
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • decreased blood sugar
  • increased blood sugar
  • decreased fluid volume
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • vulvovaginitis
  • vulvitis
  • balanitis
  • headache
  • dizziness
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • position-related dizziness
  • amnesia
  • facial paralysis
  • intracranial aneurysm
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory disturbance
  • drowsiness
  • CNS-origin vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • weight loss
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • electrocardiogram abnormalities
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • ureterolithiasis
  • hematuria
  • renal mass
  • urine retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • decreased appetite
  • obesity
  • obesity hypoventilation syndrome
  • hyperlipidemia
  • hyponatremia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystal
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • insomnia
  • anxiety
  • depression
  • sleep disorder
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • position-related vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It should be kept at room temperature between 1°C and 30°C. Storing it this way will help maintain the drug's effect and safety over time.

Appearance and packaging

Appearance

Pale yellow rectangular extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.